Ajinomoto Co., Ltd.

Japanese Foundation for Cancer Research

Ea Pharma Co., Ltd.

Koji Ohsumi

Toshihiro Hatanaka

Tamotsu Suzuki

Hiroyuki Matsueda

Munetaka Tokumasu

Nobuo Kondo

Katsumi Maezono

Takahiro Koshiba

Takashi Umemura

Akiko Onuki

Takashi Tsuji

Tadakiyo Nakagawa

Hideyuki Tanaka

Takashi Yamamoto

Tatsuya Okuzumi

Masayuki Sugiki

Yoko Kageyama

Tatsuhiro Yamada

Kazuo Ohishi

Taisuke Ichimaru

Kayo Matsumoto

Atsushi Konishi

Osamu Ikehara

Yuko Kodama

Yoshihiro Morinaga

Ryusuke Hirama

Nozomu Ishida

Ryusuke Nakagawa

Naoyuki Fukuchi

Seiji Niwa

Chikahiko Eguchi

Akira Chiba

Sayaka Asari

Takao Ikenoue

Takashi Tsuruo

Satoshi Iwayama

Yukio Iino

Koichi Fujita

Yukio Nihei

Akiyo Yamazaki

Itsuya Tanabe

Misato Noguchi

Takaaki Sekiyama

Kaori Kobayashi

Akira Kamimura

Yoshiro Kitahara

Seiji Kitajima

Chiori Ijichi

Hirozumi Eto

Hisashi Shinkai

Tomohiro Fujii

Makoto Ishii

Mizuki Kawahira

Yuka Kataba

Shimpei Ogawa

Naoko Oomuta

Yuko Iida

Kouzou Toyota

Sweetness receptor antagonists represented by formula (I): wherein each symbol is described herein, are useful for the prophylaxis or treatment of metabolic syndrome, diabetes, obesity and the like.

Sweetness receptor antagonist

Compounds represented by the following formula (I); wherein each symbol is as defined in the specification, are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Heteroarylcarboxylic acid ester derivative

The present invention provides a blood glucose elevation inhibitor having a serine protease inhibitory action, which is a novel therapeutic or prophylactic agent for obesity. A compound represented by the following formula (I) wherein each symbol is as described in the specification, or a pharmaceutically acceptable salt thereof.

Heterocyclic carboxylic acid ester derivative

Compounds represented by the following formula (I); wherein each symbol is as defined in the specification,are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Compounds represented by formula (I): wherein each symbol is as defined in the description, and pharmaceutically acceptable salts thereof are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Compounds represented by the following formula (I), are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Compounds represented by formula (I): wherein each symbol is as defined in the description, and pharmaceutically acceptable salts thereof are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes. 

The invention provides a prophylactic and therapeutic agent of diabetes mellitus, including a combination of an inhibitor of renal glucose reabsorption and a hypoglycemic agent. In accordance with the invention, hyperglycemia after meals, between meals and during fasting can be ameliorated. More specifically, in accordance with the invention, a therapeutic effect of diabetes mellitus as never been obtained by the hypoglycemic agents of the related art can be achieved.

Prophylactic and therapeutic agent of diabetes mellitus

The following fused polycyclic compound, analogues thereof or pharmaceutically acceptable salts thereof have an effect of increasing the sugar-transporting capacity and an effect of lowering the blood glucose level and, therefore, they are useful for preventing and/or treating diabetes and the like. wherein R is a methoxy group, Y is a (2-thiazolyl)-2-ethylcarbonyl group, Rand Rare hydrogen atoms, and Rand Rare methyl groups.

Fused polycyclic compounds

The present invention provides pyrazole-O-glycoside derivatives represented by the following formulae, used as a diabetic medicine. 

Pyrazole derivatives and diabetic medicine containing them

Azole compounds represented by formula I: wherein ring A is isoxazole and the like, R1 is a substituted or unsubstituted aryl group and the like, R2 is a hydrogen atom and the like, and R3 is a substituted or unsubstituted alkyl group and the like, and pharmaceutically acceptable salts thereof inhibit the physiological activity of lysophosphatidic acid (LPA), and are useful as for the prophylaxis or treatment of diseases in which inhibition of the physiological activity of LPA is useful for the prophylaxis or treatment thereof, such as diseases involving the LPA receptor.

Azole compound

The present invention provides pyrazole-O-glycoside derivatives represented by the following formulae, used as a diabetic medicine 

The present invention provides pyrazole-O-glycoside derivatives represented by the following formulae, used as a diabetic medicine.

Growing community of inventors

Kawasaki, Japan

Koji Ohsumi